A randomised phase II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer.

The aim of this trial is to investigate whether pre-operative treatment with chemotherapy plus radiation therapy has a better outcome than chemotherapy alone in patients undergoing surgery for resectable gastric cancer.

Primary Sponsor

Australasian Gastro-Intestinal Trials Group (AGITG)

Collaborating Groups

TROG Cancer Research; Canadian Cancer Trial Group (CCTG); European Organisation for Research & Treatment of Cancer (EORTC); National Health and Medical Research Council Clinical Trials Centre (NHMRC CTC)

Accrual Target

570

Final Accrual

574

Expected Date of Accrual

31 December 2020

Closing Date of Accrual

May 2021

Trial Chairperson

Professor Trevor Leong, Peter MacCallum Cancer Centre, VIC

Trial Contact

topgear.study@sydney.edu.au

Related Post

Yu Yang Soon, TROG Lung Working Party
31 July, 2025

World Lung Cancer Day: Focus on the TROG Lung Working Party

TROG WORKING PARTY IN FOCUS: 31 July 2025 To

29 July, 2025

TROG 21.07 SOCRATES HCC Trial Expands Outreach

TRIAL IN FOCUS: 29 July 2025 We’ve extended the